ABSTRACT
In this study, we have strategically designed and convergently synthesized two novel, symmetrical, and linear A-D-A-type π-conjugated donor molecules (TBDTCNR, TBDTCN), each containing a planar electron-rich 2-octylthiene-5-yl-substituted benzodithiophene (TBDT) unit as the core, flanked by octylthiophene units and end-capped with electron-deficient cyanoacetate (CNR) or dicyanovinyl (CN) units. We thoroughly characterized both of these materials and investigated the effects of the end groups (CNR, CN) on their optical, electrochemical, morphological, and photovoltaic properties. We then fabricated solution-processed bulk heterojunction organic solar cells incorporating TBDTCNR and TBDTCN. Among our tested devices, the one containing TBDTCNR and [6,6]-phenyl-C61-butyric acid methyl ester in a 1:0.40 ratio (w/w) exhibited the highest power conversion efficiency (5.42%) with a short-circuit current density (Jsc) of 9.08 mA cm(-2), an open circuit voltage (Voc) of 0.90 V, and an impressive fill factor (FF) of 0.66 under AM 1.5G irradiation (100 mW cm(-2)). The FFs of these solution-processed small-molecule organic solar cells (SMOSCs) are outstanding when compared with those recently reported for benzodithiophene (BDT)-based SMOSCs, because of the high crystallinity and excellent stacking properties of the TBDT-based compounds.
ABSTRACT
A series of 3-O-acylated (-)-epigallocatechins were synthesized and their inhibition of steroid 5α-reductase was studied. They were prepared from the reaction of EGCG with tert-butyldimethylsilyl chloride followed by reductive cleavage of the ester bond. The resultant (-)-epigallocatechins penta-O-tert-butyldimethylsilyl ether was esterified with different fatty acids then desilylated to provide the corresponding products. The activity of 3-O-acylated (-)-epigallocatechins increased with the increasing carbon numbers of the fatty acid moiety, reaching maximum for 16 carbon atoms (compound 4h) with an IC50 of 0.53 µM, which was â¼12-fold more potent than EGCG (IC50=6.29 µM). Introduction of monounsaturated fatty acid provided the most potent compound 6 (IC50=0.48 µM), which showed moderate anti-tumor activity in vivo.
Subject(s)
3-Oxo-5-alpha-Steroid 4-Dehydrogenase/metabolism , 5-alpha Reductase Inhibitors/pharmacology , Antineoplastic Agents/pharmacology , Catechin/analogs & derivatives , 5-alpha Reductase Inhibitors/chemical synthesis , 5-alpha Reductase Inhibitors/chemistry , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Catechin/chemical synthesis , Catechin/chemistry , Catechin/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Male , Mice , Mice, SCID , Models, Molecular , Molecular Structure , Stereoisomerism , Structure-Activity Relationship , Xenograft Model Antitumor AssaysABSTRACT
A series of pyrrole-indolin-2-ones were synthesized, and their inhibition profile for Aurora kinases was studied. The potent compound 33 with phenylsulfonamido at the C-5 position and a carboxyethyl group at the C-3' position selectively inhibited Aurora A over Aurora B with IC50 values of 12 and 156 nM, respectively. Replacement of the carboxyl group with an amino group led to compound 47, which retained the activity for Aurora B and lost activity for Aurora A (IC50=2.19 microM). Computation modeling was used to address the different inhibition profiles of 33 and 47. Compounds 47 and 36 (the ethyl ester analogue of 33) inhibited the proliferation of HCT-116 and HT-29 cells and suppressed levels of the phosphorylated substrates of Aurora A and Aurora B in the Western blots.
